Adiponectin, cardiac geometry and function in elderly: results from two community-based cohort studies

Authors with affiliations:

Stefan Gustafsson, MSc1; Lars Lind, MD, PhD2; Björn Zethelius, MD, PhD3; Per Venge, MD, PhD2; Allan Flyvbjerg, MD, DMSc4; Stefan Söderberg, MD, PhD5; Erik Ingelsson, MD, PhD1

1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 2Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 3Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; 4The Medical Research Laboratories, Clinical Institute, and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus, Denmark; 5Department of Public Health and Clinical Medicine, Cardiology, Umeå University Hospital, Sweden.

Address for correspondence:

Erik Ingelsson, MD, PhD, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE-171 77 Stockholm, Phone: +46-8-52482334, Fax: +46-8-314975, E-mail: erik.ingelsson@ki.se

Word count: 3568 (manuscript), 248 (abstract), 3 tables, 1 figure

Running title: Adiponectin and Cardiac Function

Copyright © 2009 European Society of Endocrinology.
ABSTRACT

Objective: Several smaller studies have indicated that adiponectin might be associated with left ventricular (LV) mass and function, but community-based studies with adequate sample size and adjustment for potential confounders are lacking. Our objective was to investigate such associations in two large community-based studies of elderly.

Design: Cross-sectional

Methods: We evaluated cross-sectional relations between serum adiponectin and echocardiographic measures of cardiac geometry and function (LV mass index, LV relative wall thickness, LV end-diastolic diameter, left atrial diameter, ejection fraction, LV isovolumic relaxation time, E/A-ratio) in 954 70-year old participants (50% women) of the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS), and in 427 71-year old men from Uppsala Longitudinal Study of Adult Men (ULSAM).

Results: In models adjusted for age, sex, body mass index, systolic blood pressure, antihypertensive treatment, antidiabetic treatment, lipid lowering medication, fasting blood glucose, total cholesterol, high-density lipoprotein cholesterol, creatinine, and smoking, adiponectin was inversely associated with ejection fraction in men (β, -1.62; 95% confidence interval [CI], -2.50, -0.75 in PIVUS; β, -1.35; 95% CI, -2.41, -0.29 in ULSAM), but not in women. After additional adjustment for N-terminal pro-brain natriuretic peptide (NT-proBNP), the association between adiponectin and ejection fraction was attenuated (β, -0.98; 95% CI, -1.86, -0.10 in PIVUS; β, -0.75; 95% CI, -1.84, 0.35 in ULSAM).

Conclusions: Serum adiponectin concentrations were associated with ejection fraction in men, and these associations were partially attenuated by NT-proBNP. Our results imply that adiponectin may be associated with systolic function through pathways that involves natriuretic peptides.
Keywords: adipokines, cardiac geometry, cardiac function, ejection fraction
INTRODUCTION

Cardiovascular disease (CVD) is a leading cause of death accounting for about one third of the total number of deaths in the world. It is a major contributor to the increased burden on public health care.\textsuperscript{1, 2} Recent studies have demonstrated the critical role of adipose tissue as an endocrine organ that, by secretion of adipocytokines, can affect several processes that can lead to development of CVD.\textsuperscript{3} Adiponectin, the most abundant adipocytokine, is recognized as a key regulator of insulin resistance, tissue inflammation, and other patophysiological processes.\textsuperscript{4}

The role of adiponectin in relation to cardiac geometry and function has attracted some recent attention. Several studies performed in small study samples, mostly in patients with preexisting disease, such as type 2 diabetes, hypertension or obesity, have reported inverse associations between adiponectin and left ventricular (LV) mass,\textsuperscript{5-9}, and diastolic dysfunction.\textsuperscript{7, 9} Similarly, a larger sample of healthy Japanese men has presented an association between lower levels of adiponectin and dichotomous ECG-LV hypertrophy (ECG-LVH) as outcome.\textsuperscript{10} There are however very few large, community-based studies with adequate adjustment for potential confounders to elucidate these relations in greater detail; to our knowledge, only one prior study has investigated the relation of adiponectin with LV geometry and function in a moderately large sample of healthy individuals.\textsuperscript{11} In this study, circulating adiponectin increased in parallel with brain natriuretic peptide (BNP) and was positively associated with higher LV end-diastolic diameter which could indicate depressed cardiac function. A potential role for the balance of adiponectin and natriuretic peptides in the development of cardiac dysfunction has also been indicated by studies showing increased levels of both adiponectin and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with heart failure.\textsuperscript{12-14}
Based on these previous data, we hypothesized that circulating adiponectin would be associated with LV geometry and function, and that this would be partially mediated through pathways involving natriuretic peptide levels. We tested these hypotheses in two large, community-based samples of elderly who underwent echocardiography and measurements of adiponectin and NT-proBNP.
SUBJECTS AND METHODS

Study samples

The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) has been described in detail previously\(^\text{15}\) and on the Internet (http://www.medsci.uu.se/pivus/pivus.htm). In brief, all 70-year-old individuals residing in Uppsala, Sweden between April 2001 and June 2004 were eligible for the study. By random selection, 2025 subjects were invited, of which 1016 subjects (50% women) were examined within one month of their 70\(^{th}\) birthday in order to standardize for age. After exclusion of individuals without valid adiponectin measurements (n=9), echocardiography readings (n=30), or all clinical characteristics needed for multivariable analysis (n=23), the eligible study sample was 954 participants.

The Uppsala Longitudinal Study of Adult Men (ULSAM) has been described elsewhere\(^\text{16}\) and on the Internet (http://www.pubcare.uu.se/ULSAM/). Briefly, the study was initiated in 1970-74 when all 50-year-old men living in Uppsala County, Sweden were invited to participate. The participants were re-examined in August 1991 to May 1995, at the approximate age of 71 years. Out of 1681 invited individuals, 1221 (73% of those still alive and living in Uppsala) participated in the follow-up. An echocardiographic examination was performed in a random sub-sample of 482 individuals, and after exclusion of participants without valid adiponectin measurements (n=16) or all clinical measures used in the analyses (n=39), the eligible sample was 427 individuals. Both studies were approved by the Ethics Committee of Uppsala University, and all participants provided written informed consent.

Assessment and definitions of clinical covariates

Similar and standardized methods were used in both studies for collection of anthropometrical measurements, blood pressure, fasting blood and urine samples, and included a questionnaire
regarding medical history, smoking habits and regular medication. All participants went through an overnight fast prior to the investigation, in which both medication and smoking were disallowed. Body Mass Index (BMI) was calculated by dividing weight (kg) with squared height (m$^2$). Blood pressure was measured by a calibrated mercury sphygmomanometer to the nearest even mmHg after at least 30 min of rest, and the mean of three (PIVUS) or two (ULSAM) recordings was used. Lipid variables, creatinine and fasting blood glucose were measured using standard laboratory techniques. NT-proBNP was measured in PIVUS and ULSAM with a sandwich immunoassay on an Elecsys 2010 (Roche Diagnostics, Basle, Switzerland) at an analytical range of 20 to 35,000 ng/l. The total coefficient of variation was 3.3% at a level of 209 ng/l and 3.0% at a level of 7.4 ng/l.

Echocardiographic parameters were measured with a comprehensive two-dimensional and Doppler echocardiography, performed with a Acuson XP124 cardiac ultrasound unit (Acuson, California, USA) approximately one week after the main examination by Dr. Lind who was blinded to the clinical data. The echocardiographic measures included LV end-diastole diameter (LVEDD), left atrial diameter, ejection fraction, LV isovolumic relaxation time, E/A ratio, interventricular septal thickness (IVS), LV posterior wall thickness (PW). LV relative wall thickness (RWT) was calculated as (IVS+PW)/LVEDD and LV mass (LVM) as 0.8*(1.04*([IVS+LVEDD+PW]$^3$-LVEDD$^3$)+0.6 g. LV mass index (LVMI) was obtained by indexing LVM divided by height to the power of 2.7 (LVM/m$^{2.7}$). Ejection fraction was calculated from M-mode recordings according to the method of Teichholz. LV geometry was categorized as: normal (LVMI ≤51 g/m$^{2.7}$; RWT ≤0.45), eccentric LV hypertrophy (LVMI >51 g/m$^{2.7}$; RWT ≤0.45), concentric remodeling (LVMI ≤51 g/m$^{2.7}$; RWT >0.45), and concentric LV hypertrophy (LVMI >51 g/m$^{2.7}$; RWT >0.45).
Adiponectin measurements

Adiponectin in samples from PIVUS, frozen for 1-3 years, was analysed with a double-antibody radioimmunoassay (RIA; Linco Res., St. Louis, MO, USA). The total coefficient of variation for adiponectin was 15.2% at low (2–4 µg/ml) and 8.8% at high (26–54 µg/ml) levels. The measurement of adiponectin in ULSAM has been described in detail previously.\textsuperscript{22} In brief, serum adiponectin was measured in a validated in-house time-resolved immunofluorometric assay based on commercial reagents from R&D Systems (Abingdon, UK). The analyses were done in samples frozen in -70°C for 11±2 years, without previous thaw-freeze cycles, collected at the examination at age 71 between 1991 and 1995. The average intra-assay and inter-assay coefficient of variation averaged less than 5 and 10%, respectively.\textsuperscript{12}

Statistical methods

All variables were normally distributed, except E/A-ratio and fasting glucose; these two were logarithmically transformed in order to promote normality. As circulating adiponectin concentrations may differ between sexes, levels were z-score transformed in each sex separately before pooling data in PIVUS. This approach also allowed comparisons of β coefficients in PIVUS and ULSAM; thus, the β coefficients presented represent a 1-standard deviation increase in adiponectin. The association between adiponectin, cardiac geometry and function were analyzed in age- and sex-adjusted, as well as multivariable linear regression models with echocardiographic measures (LV mass index, relative wall thickness, end-diastolic diameter, left atrial diameter, ejection fraction, isovolumic relaxation time, E/A-ratio) as dependent variables in separate models. The multivariable regression models were adjusted for age, sex (only in PIVUS), BMI, systolic blood pressure, antihypertensive treatment, antidiabetic treatment, lipid lowering medication, log fasting blood glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, creatinine, and smoking (no, former,
current). To address a potential mediating role of natriuretic peptides in the relation of adiponectin with cardiac function, we added NT-proBNP to the multivariable-adjusted models with ejection fraction, isovolumic relaxation time or E/A-ratio as outcomes. Interactions were tested by two-way interaction terms between sex and adiponectin with echocardiographic variables as the dependent variables in separate models. Also, to avoid a potentially confounding effect of co-morbidities with heart disease, analyses were also performed in sub-samples consisting of 804 (PIVUS) and 356 (ULSAM) individuals without history of myocardial infarction, heart failure, angina pectoris or interventional treatment of the coronary arteries, or with significant valvular diseases detected on the echocardiogram. Adiponectin levels in relation to groups of cardiac geometry was calculated as age- and-sex-adjusted least square means of adiponectin grouped by categories of cardiac geometry in the PIVUS study and the results were visualized in a figure. Two-tailed significance values were given with $P<0.05$ regarded as significant. The statistical software package STATA 10.1 (Stata Corporation, College Station, TX, USA) was used for all analyses.
RESULTS

Table 1 presents the clinical characteristics along with measures of cardiac geometry and function, separately for PIVUS and ULSAM.

Associations between adiponectin and measures of cardiac geometry
In PIVUS, adiponectin was inversely associated with LV mass index, LV relative wall thickness, and left atrial diameter in age- and sex-adjusted analyses (Table 2, left column). Consistent with this, adiponectin concentrations were significantly lower in individuals with eccentric hypertrophy, concentric remodeling, and concentric hypertrophy compared with individuals with normal cardiac geometry (Figure 1). The associations of adiponectin with LV geometry were non-evident in multivariable-adjusted analyses (Table 2, right column). In secondary analyses, associations between adiponectin and LV mass (without indexing for height) were almost identical to those incorporating LV mass index (data not shown). Exploratory analyses demonstrated that BMI was the most important confounder of the associations of adiponectin and cardiac geometry, as the addition of BMI to the age- and sex-adjusted analyses rendered all associations non-significant (P=0.52; 0.14; and 0.91). In ULSAM, adiponectin was not significantly associated with measures of cardiac geometry in either age- and sex-adjusted or multivariable-adjusted analyses (Table 3).

Associations of adiponectin and measures of cardiac function
In multivariable-adjusted models including BMI, circulating adiponectin was inversely associated with ejection fraction in PIVUS (Table 2), as well as in ULSAM (Table 3). For each standard deviation increase of adiponectin, ejection fraction decreased with 1.2% (PIVUS) or 1.3% (ULSAM). Sex was found to be an effect modifier in the association of adiponectin with ejection fraction (P for interaction=0.063); the association was evident in
men (β, -1.62; 95% confidence interval [CI], -2.50, -0.75; P<0.0001), but not in women (β, -0.27; 95% CI, -1.02, 0.47; P=0.47. None of the other interaction terms were significant. The inverse relation between adiponectin and ejection fraction remained similar when excluding individuals with known prior CVD (β, -0.70; 95% CI, -1.29, -0.12; P=0.019; β, -1.62; 95% CI, -2.70, -0.55; P=0.003, in PIVUS and ULSAM, respectively). Exploratory analyses revealed that HDL cholesterol and BMI acted as negative confounders, i.e. they increased the magnitude of the association between adiponectin and ejection fraction when added to the age-and sex-adjusted model. LV mass had no effect on the association between adiponectin and ejection fraction when added to the multivariable model, nor did further adjustment for C-reactive protein or homeostasis model assessment insulin resistance (HOMA-IR; data not shown).

To address the role of natriuretic peptides in mediating the association of adiponectin with cardiac function, we added NT-proBNP to the multivariable-adjusted model with ejection fraction as outcome. The association between adiponectin and ejection fraction was attenuated in both PIVUS (β, -0.68; 95% CI, -1.25, -0.10; P=0.021) and ULSAM (β, -0.75; 95% CI, -1.84, 0.35; P=0.18). Consistent with the above sex-stratified analyses, the association between adiponectin and ejection fraction was attenuated, but still significant (β, -0.98; 95% CI, -1.86, -0.10; P=0.029) in men and non-significant in women (β, -0.14; 95% CI, -0.88, 0.60; P=0.71) in PIVUS. Further, the attenuation was lesser in individuals without prior CVD (β, -0.69 and -0.61; 95% CI, -1.28, -0.11 and -1.20, -0.03, without and with adjustment for NT-proBNP, respectively), but more pronounced in a sub-sample with individuals having prior CVD (β, -2.30 and -1.00; 95% CI, -3.90, -0.69 and -2.76, -0.75, without and with adjustment for NT-proBNP, respectively).

With our sample sizes, we had at least 85% (PIVUS) or 81% (ULSAM) statistical power to detect an increment to the model R² of 0.01 (PIVUS) or 0.02 (ULSAM) for all
measures of cardiac function and geometry (at alpha=0.05).
DISCUSSION

Our principal findings are twofold. First, adiponectin was inversely associated with ejection fraction in elderly men. This association was independent of potential confounders including BMI, and it was also evident in a sub-sample after exclusion of individuals with any previously known CVD. We did not observe an association between adiponectin and ejection fraction in women. Second, our results indicate that NT-proBNP may act as a partial mediator of the association of adiponectin with ejection fraction, as the $\beta$ coefficients of associations between adiponectin with ejection fraction were 40-50% lower when NT-proBNP was included in the models. Even if distinct conclusions cannot be drawn from cross-sectional studies, this apparent attenuation of effect may indicate that the associations of adiponectin and natriuretic peptides with LV systolic function could stem from the same patophysiological pathways. The validity of our novel findings are underscored by the consistent findings in two large, independent community-based samples.

During recent years, the role of adiponectin has been of interest in several physiological processes, but there are only a few small studies trying to elucidate its relation with cardiac structure and function. Some prior studies have reported an inverse association between adiponectin and cardiac geometry; primarily LV mass, $^5-^9$ but also ECG-LVH, $^10$ whereas we observed such associations only in age- and sex-adjusted analyses, but not after adjustment for BMI. Consistent with this, adiponectin levels differed significantly between individuals with normal geometry and individuals with categories of hypertrophy and/or remodeling, adjusted for age and sex (Figure 1). However, further adjustment for BMI rendered this association not significant, which highlights the role of BMI as a confounder of the association between adiponectin and cardiac geometry. Furthermore, in a study including 186 hypertensive patients and 89 healthy controls, high adiponectin associated inversely with LV isovolumic relaxation time and positively with E/A ratio, $^7$ i.e. with less diastolic dysfunction.
However, these studies have been performed in small samples of younger patients, often with preexisting disease, such as type 2 diabetes, hypertension and obesity, and confounders have not always been adjusted for. These differences in study design are plausible explanations for the discrepancies.

Circulating adiponectin levels are higher in patients with prevalent heart failure, and has been shown to correlate with circulating NT-proBNP in patients with heart failure. Also, in heart failure patients, adiponectin has been demonstrated to be prognostic of mortality and hospitalizations for heart failure. Recently, we reported that neither circulating adiponectin nor genetic variation in the adiponectin gene (ADIPOQ) predicted incident heart failure in the ULSAM study, where we followed 946 men without heart failure for up to 11 years. This was corroborated by a recent report from the Framingham Heart Study, where no associations of adiponectin with incident heart failure was found, whereas circulating resistin was associated with incident heart failure, even when taking prevalent coronary heart disease, obesity, and measures of insulin resistance and inflammation into account. In a recent study of 608 healthy individuals from Japan in an age group that was comparable to that of the present study (mean age, 62 years), adiponectin was increased with higher LV end-diastolic diameter even after adjustment for age, sex and BMI. Furthermore, adiponectin tracked with BNP; thus, the authors suggested that adiponectin might reflect some aspects of cardiac function. This was supported by a recent case-control study of 250 CVD patients and 250 controls were circulating adiponectin levels were positively associated with NT-proBNP; especially in the higher range of NT-proBNP levels. Taken together, these observations clearly substantiate the findings of the present study.

To put the decrease of 1.2% in ejection fraction per 1-SD increase of adiponectin in perspective and understand its potential clinical relevance, we compared this effect size with the other two significant continuous predictors of ejection fraction in our multivariable-
adjusted model (change in ejection fraction, -0.93% and 1.00% per 1-SD increase of BMI and systolic blood pressure, respectively). Nevertheless, even if adiponectin demonstrated the highest effect size among the clinical predictors, the question of how large ejection fraction change that is clinically relevant is not trivial, since it depends on other factors, such as age, sex, and concomitant congestive heart failure, and where in the distribution of ejection fraction this change occurs (as there is a non-linear relation of ejection fraction with outcome). However, as an example, a 5% increment in ejection fraction was associated with a 13% lower hazard of death in individuals with heart failure in the Framingham Heart Study.\textsuperscript{27}

In any case, it is important to emphasize that the main objective of the present study was to disentangle mechanisms linking adiponectin with cardiac geometry and function rather than finding clinically useful predictors of LV function.

In the present study, we observed associations of adiponectin with ejection fraction in men, but not in women. This could possibly be explained by previously demonstrated sex differences in circulating adiponectin levels in human samples, with females having higher levels than males.\textsuperscript{28, 29} There are some indications that this sex difference in circulating levels of adiponectin could be explained by an inhibitory influence of androgens. One study demonstrated significantly increased levels of adiponectin in castrated male mice, whereas injections of testosterone in these mice decreased plasma adiponectin.\textsuperscript{30} Analysis in cultured adipocytes showed that testosterone and 5α-DHT suppressed the secretion of adiponectin. Since adiponectin mRNA remained unaffected by testosterone treatment vitro and in vivo, the existence of a testosterone-regulated factor involved in the secretion of adiponectin was suggested.\textsuperscript{30} Consistent with this, a small study in normal men reported significantly increased concentrations of adiponectin upon experimental reduction of testosterone and decreased levels after administration of testosterone.\textsuperscript{31}
The notion that adiponectin is associated with prevalent, but not incident heart failure, have spurred the idea that the cardiac cachexia seen in many heart failure patients could lead to lower fat mass and consequently higher adiponectin. However, the present study was performed in healthy, free-living individuals without overt disease, and the inverse association between adiponectin and systolic function was also present in a healthier sub-sample (after exclusion of all individuals with any prior CVD) and after adjustments for BMI along with other potential confounders. These observations, along with the prior study of similarly healthy elderly individuals from Japan,\textsuperscript{11} suggest that cardiac cachexia is unlikely to be the sole reason for the associations of circulating adiponectin, NT-proBNP and LV systolic function. Nevertheless, it should be noted that the attenuation of the association of adiponectin with ejection fraction was even more pronounced in a sub-sample of individuals with prior CVD. However, this observation needs to be confirmed in other settings, as the sample size for these secondary analyses were too modest to draw firm conclusions.

Given the previously reported associations between increased adiponectin and BNP concentrations along with heart failure,\textsuperscript{12-14} or LV dilation in individuals without overt disease,\textsuperscript{11} we hypothesized that adiponectin would be involved in the same cardioregulatory pathway as BNP. Our analyses showed that adjustment for NT-proBNP partially attenuated the association between adiponectin and ejection fraction. A potential explanation could be that BNP is along the pathway by which adiponectin is associated with LV systolic function. Previous studies have shown that naturetic peptides exhibit a lipolytic effect on human adipose tissue through a cGMP-dependent pathway\textsuperscript{32-34} that may explain the linkage between adiponectin and BNP. Circulating adiponectin has been suggested to be a marker of total stimulated adipose tissue triacylglycerol lipolytic capacity \textit{in vivo} in humans.\textsuperscript{35} Another study demonstrated that infusion of synthetic atrial natriuretic peptide (ANP) increased levels of total and high-molecular weight adiponectin in patients with heart failure.\textsuperscript{36} In addition, a
preliminary study has shown that both ANP and BNP increased the adiponectin mRNA expression in a dose-dependent manner, mediated through the cGMP-dependent pathway. Strengths of the present study include the confirmation of the study results in two large, independent community-based samples with comprehensive assessment of cardiac geometry and function. However, some limitations should be acknowledged. First, since both study samples consisted exclusively of elderly individuals of Northern European ethnicity, it is unknown if the results can be generalized to younger individuals or other ethnicities. Second, measures of different multimeric forms of serum adiponectin were not available for the present study. This could be of some importance, since some studies suggest a difference in biological activity between different isoforms of adiponectin with regard to metabolic abnormalities. Third, as this is a cross-sectional study, causality cannot be elucidated nor can it be determined if cardiac geometry and function is related to the longitudinal tracking of adiponectin concentrations. Fourth, ejection fraction was measured according to the Teichholz formula using M-mode in both cohorts. This way to evaluate ejection fraction has its known limitations since it does not take into consideration dyskinesia in other segments than those included in the M-mode recording. Despite this limitation, this way of measuring ejection fraction is still used very frequently in the clinical setting, a substantial part of the literature regarding the predictive power of ejection fraction, and inclusion criteria in landmark heart failure treatment trials are based on this method. Fifth, the samples were stored in -70°C for 1-3 years (PIVUS) and 11±2 years (ULSAM) before being analyzed. However, at the time of collection, the samples were ideally treated to limit any influence on stability of samples. The effect of frozen storage on adiponectin levels has to our best knowledge been investigated under a maximum of 30 months, reporting no discernible effect of mean plasma adiponectin levels. We are not aware of any other studies with longer follow-up, but most peptide
hormones has been shown to be fairly stable, some peptides even during long-term storage up to 25 years.\textsuperscript{41}

In conclusion, in our two community-based samples of elderly, adiponectin concentrations were inversely associated with ejection fraction in men, even after adjustment for potential confounders including BMI. These associations were partially attenuated by additional adjustment for NT-proBNP, indicating that adiponectin may be associated with depressed LV systolic function through pathways shared with natriuretic peptides. Further studies are required to confirm our findings, and to establish the biological pathways linking adiponectin, natriuretic peptides and cardiac function.
ACKNOWLEDGEMENTS

Sources of support: This work was supported by the Swedish Research Council (grant number 2007-2135), Swedish Heart-Lung Foundation (grant number 20070212), Royal Swedish Academy of Science, Linnéus Foundation for Medical Research, the Foundation of Erik, Karin och Gösta Selander, the Foundation of Fredrik and Ingrid Thuring, the Foundation of Åke Wiberg, the Northern Sweden Councils (Visare Norr), the Swedish Society for Medical Research, AstraZeneca R&D Mölndal and the Danish Medical Research Council.

Role of the sponsor: The sponsors had no role in the study design, analyses, writing or decision to publish the manuscript.

Conflicts of interest: None of the authors have any conflicts of interest to declare.
REFERENCES


7. Hong SJ, Park CG, Seo HS, Oh DJ & Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. *Blood Press* 2004 **13** 236-242.


FIGURE LEGENDS

Figure 1. Age-and-sex-adjusted least square means of adiponectin grouped by categories of cardiac geometry in the PIVUS study (N=954)
Figure 1.
254x190mm (96 x 96 DPI)
Table 1. Clinical characteristics and echocardiographic measures*  

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>PIVUS (N=954)</th>
<th>ULSAM (N=427)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>70.2 (0.2)</td>
<td>71.2 (0.4)</td>
</tr>
<tr>
<td>Women (%)</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.1 (4.3)</td>
<td>26.1 (3.2)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>150 (23)</td>
<td>149 (19)</td>
</tr>
<tr>
<td>Antihypertensive treatment (%)</td>
<td>31</td>
<td>37</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>5.4 (1.0)</td>
<td>5.8 (1.0)</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.5 (0.4)</td>
<td>1.3 (0.3)</td>
</tr>
<tr>
<td>Lipid lowering treatment (%)</td>
<td>16</td>
<td>9</td>
</tr>
<tr>
<td>Fasting plasma glucose (mmol/L)</td>
<td>5.4 (1.6)</td>
<td>5.8 (1.4)</td>
</tr>
<tr>
<td>Diabetes treatment (%)</td>
<td>6.6</td>
<td>5.4</td>
</tr>
<tr>
<td>Creatinine, (µmol/L)</td>
<td>80 (20)</td>
<td>94 (14)</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never: 49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous: 41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current: 10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adiponectin (mg/L)</td>
<td>7.1 (4.3)</td>
<td>10.6 (4.4)</td>
</tr>
<tr>
<td>LV mass index (g/m²)</td>
<td>43.1 (13.2)</td>
<td>58.8 (13.2)</td>
</tr>
<tr>
<td>LV relative wall thickness</td>
<td>0.44 (0.09)</td>
<td>0.41 (0.06)</td>
</tr>
<tr>
<td>LV end-diastolic diameter (mm)</td>
<td>47 (5)</td>
<td>52 (5)</td>
</tr>
<tr>
<td>Left atrial diameter (mm)</td>
<td>39 (7)</td>
<td>42 (6)</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>67 (8)</td>
<td>64 (10)</td>
</tr>
<tr>
<td>LV isovolumic relaxation time (ms)</td>
<td>121 (21)</td>
<td>124 (23)</td>
</tr>
<tr>
<td>E/A-ratio</td>
<td>0.96 (0.28)</td>
<td>0.95 (0.34)</td>
</tr>
</tbody>
</table>

* Results are expressed as means (standard deviations) or proportions.

Abbreviations: PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; ULSAM, Uppsala Longitudinal Study of Adult Men; BMI, body mass index; HDL, high density lipoprotein; CI, confidence interval; LV, left ventricular.
**Table 2.** Adiponectin in relation to echocardiographic measures in the PIVUS study (N=954) *

<table>
<thead>
<tr>
<th></th>
<th>Associations with serum adiponectin</th>
<th>Age and sex-adjusted</th>
<th>Multivariable-adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>β (95% CI)</strong></td>
<td><strong>P-value</strong></td>
<td><strong>β (95% CI)</strong></td>
</tr>
<tr>
<td>LV mass index (g/m²); n=895</td>
<td>-1.48 (-2.34; -0.62)</td>
<td>0.001</td>
<td>0.42 (-0.33; 1.17)</td>
</tr>
<tr>
<td>LV relative wall thickness; n=895</td>
<td>-0.01 (-0.01; -0.00)</td>
<td>0.012</td>
<td>-0.00 (-0.01; 0.00)</td>
</tr>
<tr>
<td>LV end-diastolic diameter (mm); n=897</td>
<td>-0.21 (-0.54; 0.12)</td>
<td>0.21</td>
<td>0.32 (-0.03; 0.67)</td>
</tr>
<tr>
<td>Left atrial diameter (mm); n=924</td>
<td>-0.70 (-1.10; -0.29)</td>
<td>0.001</td>
<td>0.25 (-0.13; 0.63)</td>
</tr>
<tr>
<td>Ejection fraction (%); n=810</td>
<td>-0.73 (-1.25; -0.20)</td>
<td>0.007</td>
<td>-1.16 (-1.73; -0.58)</td>
</tr>
<tr>
<td>LV isovolumic relaxation time (ms); n=871</td>
<td>-0.75 (-2.13; 0.64)</td>
<td>0.29</td>
<td>0.79 (-0.57; 2.16)</td>
</tr>
<tr>
<td>log E/A-ratio; n=913</td>
<td>0.02 (-0.00; 0.03)</td>
<td>0.070</td>
<td>0.00 (-0.01; 0.02)</td>
</tr>
</tbody>
</table>

* Values are beta coefficients (95% confidence intervals) from models with adiponectin together with age and sex (age-and sex-adjusted models), or age, sex, BMI, systolic blood pressure, anti-hypertensive medication, anti-diabetic medication, lipid-lowering medication, log fasting glucose, total cholesterol, HDL cholesterol, creatinine, and smoking (multivariate-adjusted models) as independent variables, and echocardiographic measures as dependent variables in separate models. Beta coefficients represent change in echocardiographic measure (in untransformed units) per 1-SD increase in adiponectin.

Abbreviations: See **Table 1**.
**Table 3.** Adiponectin in relation to echocardiographic measures in the ULSAM study (N=427)*

<table>
<thead>
<tr>
<th></th>
<th>Age-adjusted</th>
<th></th>
<th>Multivariable-adjusted</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)</td>
<td>P-value</td>
<td>β (95% CI)</td>
<td>P-value</td>
</tr>
<tr>
<td>LV mass index (g/m²); n=427</td>
<td>-0.26 (-1.50; 0.98)</td>
<td>0.69</td>
<td>1.08 (-0.20; 2.36)</td>
<td>0.10</td>
</tr>
<tr>
<td>LV relative wall thickness (mm); n=427</td>
<td>-0.00 (-0.01; 0.00)</td>
<td>0.26</td>
<td>-0.00 (-0.01; 0.01)</td>
<td>0.66</td>
</tr>
<tr>
<td>LV end-diastolic diameter (mm); n=427</td>
<td>0.09 (-0.41; 0.59)</td>
<td>0.73</td>
<td>0.32 (-0.24; 0.88)</td>
<td>0.26</td>
</tr>
<tr>
<td>Left atrial diameter (mm); n=423</td>
<td>-0.31 (-0.86; 0.24)</td>
<td>0.27</td>
<td>0.34 (-0.26; 0.94)</td>
<td>0.27</td>
</tr>
<tr>
<td>Ejection fraction (%); n=385</td>
<td>-0.91 (-1.86; 0.04)</td>
<td>0.059</td>
<td>-1.35 (-2.41; -0.29)</td>
<td>0.013</td>
</tr>
<tr>
<td>LV isovolumic relaxation time (ms); n=378</td>
<td>0.89 (-1.39; 3.18)</td>
<td>0.44</td>
<td>1.69 (-0.89; 4.27)</td>
<td>0.20</td>
</tr>
<tr>
<td>log E/A-ratio; n=387</td>
<td>0.01 (-0.02; 0.04)</td>
<td>0.45</td>
<td>0.01 (-0.02; 0.04)</td>
<td>0.56</td>
</tr>
</tbody>
</table>

* Values are beta coefficients (95% confidence intervals) from models with adiponectin together with age (age-adjusted models), or age, BMI, systolic blood pressure, anti-hypertensive medication, anti-diabetic medication, lipid-lowering medication, log fasting glucose, total cholesterol, HDL cholesterol, creatinine, and smoking (multivariate-adjusted models) as independent variables, and echocardiographic measures as dependent variables in separate models. Beta coefficients represent change in echocardiographic measure (in untransformed units) per 1-SD increase in adiponectin.

Abbreviations: See Table 1.